Prabhu VS, et al. - In this work, an estimation was performed of 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Observations revealed fewer CDI-associated readmissions among bezlotoxumab-treated inpatients compared with placebo-treated inpatients, particularly in participants aged ≥65 years and with severe CDI.